title: ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
abstract: OBJECTIVE
  Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients.
  
  
  METHODS
  We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset.
  
  
  RESULTS
  Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of < or = 1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01).
  
  
  CONCLUSIONS
  These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.
authors.affiliation: Stanford University School of Medicine, Stanford, Calif, USA.
authors.forename: Gregory W
authors.initials: GW
authors.lastname: Albers
authors.forename: Wayne M
authors.initials: WM
authors.lastname: Clark
authors.forename: Kenneth P
authors.initials: KP
authors.lastname: Madden
authors.forename: Scott A
authors.initials: SA
authors.lastname: Hamilton
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003710:Demography; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D020300:Intracranial Hemorrhages / Q000209:etiology; D008297:Male; D008875:Middle Aged; D018401:Sample Size; D012720:Severity of Illness Index; D020521:Stroke / Q000188:drug therapy*; D015996:Survival Rate; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D010959:Tissue Plasminogen Activator